Lipigon Pharmaceuticals AB (publ) (STO:LPGO)

Market Cap	908.90K -94.7%
Revenue (ttm)	n/a
Net Income	-32.44M
EPS	-0.08
Shares Out	605.93M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	141,352,400
Open	0.0027
Previous Close	0.0027
Day's Range	0.0011 - 0.0027
52-Week Range	0.0011 - 0.1935
Beta	0.13
Analysts	n/a
Price Target	n/a
Earnings Date	May 25, 2026

About STO:LPGO

Lipigon Pharmaceuticals AB (publ), a clinical-stage pharmaceutical company, develops drugs for lipid related diseases in Sweden. Its product pipeline consists of Lipisense project, which is in phase II for the treatment of severe hypertriglyceridemia disease; Dyslipidemia project, which is in preclinical trial to treat cardiovascular disease and severe hypertriglyceridemia; and CAP project, which is in preclinical trial to treat and prevent lung injury associated with community-acquired pneumonia. The company has a license agreement with Leader...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 7
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: LPGO

Financial Performance

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

May 20, 2026

Data Sources Report a data error